You have 9 free searches left this month | for more free features.

Esophageal Squamous Cell Carcinoma

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Sintilimab, Chemotherapy)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 30, 2023

Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

Recruiting
  • Esophageal Squamous Cell Carcinoma
    • Shijiazhuang, Hebei, China
      Department of Thoracic Surgery, Fourth Hospital of Hebei Medical
    Oct 25, 2023

    Advanced Esophageal Squamous Carcinoma With Oligometastases Trial (simultaneous with radiotherapy, synchronous with

    Not yet recruiting
    • Advanced Esophageal Squamous Carcinoma With Oligometastases
    • simultaneous with radiotherapy
    • synchronous with radiotherapy
    • (no location specified)
    Nov 16, 2023

    Metastatic Esophageal Squamous Cell Carcinoma Trial in Qingdao (TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1

    Recruiting
    • Metastatic Esophageal Squamous Cell Carcinoma
    • TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors(Sintilimab)
    • Qingdao, Shandong, China
    • +1 more
    Nov 13, 2023

    Esophageal Squamous Cell Carcinoma Trial in Wuhan (no intervention)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • no intervention
    • Wuhan, Hubei, China
      Renmin hosptial of Wuhan University
    Jul 29, 2023

    Esophageal Squamous Cell Carcinoma Trial in Shanghai (Tirelizumab, Nab paclitaxel, Carboplatin)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Shanghai, Shanghai, China
      Ruijin hospital, Shanghai jiaotong university school of medicine
    Nov 6, 2023

    Esophageal Squamous Cell Carcinoma Trial (Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin)

    Not yet recruiting
    • Esophageal Squamous Cell Carcinoma
    • Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin
    • (no location specified)
    Aug 17, 2023

    Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (LBL-007,

    Not yet recruiting
    • Esophageal Cancer
    • +2 more
    • (no location specified)
    Aug 21, 2023

    Esophageal Squamous Cell Carcinoma Trial (LY01015, Fluorouracil, Cisplatin)

    Not yet recruiting
    • Esophageal Squamous Cell Carcinoma
    • (no location specified)
    Aug 28, 2023

    Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma Trial in Shanghai

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • +2 more
    • LDRT+CFRT
    • +2 more
    • Shanghai, China
    • +1 more
    Aug 3, 2023

    Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors Trial in Zhengzhou (IBI110+Sintilimab)

    Not yet recruiting
    • Esophageal Squamous Cell Carcinoma (ESCC)
    • PD-1 Inhibitors
    • Zhengzhou, Henan, China
      Feng Wang
    Oct 9, 2023

    Esophageal Squamous Cell Carcinoma Trial in Shantou (Tislelizumab)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Shantou, Guangdong, China
      Cancer Hospital of Shantou University Medical College
    Aug 2, 2023

    Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Chengdu (Camrelizumab, Dalpiciclib 100mg,

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Head and Neck Squamous Cell Carcinoma
    • Chengdu, Sichuan, China
      West China Hospital, Sichuan University
    Oct 25, 2023

    Minimal Residual Disease, Esophageal Squamous Cell Carcinoma Trial in Guangzhou

    Not yet recruiting
    • Minimal Residual Disease
    • Esophageal Squamous Cell Carcinoma
      • Guangzhou, Guangdong, China
        Guangdong Provincial People's Hospital
      Jun 10, 2023

      Esophageal Squamous Cell Carcinoma Trial in Nanjing (Carrelizumab, Paclitaxel injection, Cisplatin)

      Enrolling by invitation
      • Esophageal Squamous Cell Carcinoma
      • Nanjing, China
        The First Affiliated Hospital of Nanjing Medical University
      Sep 19, 2023

      Esophageal Cancer Trial in Wuhan

      Recruiting
      • Esophageal Cancer
        • Wuhan, Hubei, China
          Renmin hosptial of Wuhan University
        Jun 7, 2023

        Esophageal Squamous Cell Carcinoma Trial in Wuhan (Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin)

        Not yet recruiting
        • Esophageal Squamous Cell Carcinoma
        • Intensity-modulated radiotherapy (IMRT)
        • +3 more
        • Wuhan, Hubei, China
          Renmin hosptial of Wuhan University
        Jun 16, 2023

        Resectable Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy Trial (cadonilimab+chemo)

        Not yet recruiting
        • Resectable Esophageal Squamous Cell Carcinoma
        • Neoadjuvant Therapy
        • (no location specified)
        Apr 18, 2023

        Esophageal Squamous Cell Carcinoma Trial (XH-30002 capsule, Afatiinb tablet)

        Not yet recruiting
        • Esophageal Squamous Cell Carcinoma
        • XH-30002 capsule
        • Afatiinb tablet
        • (no location specified)
        Jun 25, 2023

        The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC Trial in Hanzhou (Cadonilimab Combined Albumin-paclitaxel,

        Recruiting
        • The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
        • Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
        • Hanzhou, Zhejiang, China
          Lulu Liu
        Jul 14, 2023

        NLR and Its Association With Efficacy of Immunochemotherapy in

        Recruiting
        • Esophageal Squamous Cell Carcinoma
        • +2 more
          • Guangzhou, Guangdong, China
            Guangdong Provincial People's Hospital
          Nov 10, 2023

          Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)

          Recruiting
          • Esophageal Squamous Cell Carcinoma
          • Cadonilimab combined Anlotinib
          • Hangzhou, Zhejiang, China
            2nd Affiliated Hospital, School of Medicine, Zhejiang University
          Aug 6, 2023

          Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy Trial in Shanghai (Tislelizumab)

          Recruiting
          • Esophageal Squamous Cell Carcinoma
          • +2 more
          • Shanghai, Shanghai, China
            Shanghai chest hospital
          Sep 24, 2023

          Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (Radiotherapy, Toripalimab)

          Not yet recruiting
          • Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
          • (no location specified)
          Mar 17, 2023

          Esophageal Squamous Cell Carcinoma Trial in Anyang, Zhengzhou (AK104, nab-paclitaxel, carboplatin)

          Not yet recruiting
          • Esophageal Squamous Cell Carcinoma
          • AK104, nab-paclitaxel, carboplatin
          • Anyang, Henan, China
          • +1 more
          Jun 1, 2023